Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis

被引：0
|
作者：
Kako, Shinichi
Fujiwara, Shin-ichiro
Sato, Miki
Kimura, Shun-ichi
Nakasone, Hideki
Ohashi, Kazuteru
Hidaka, Michihiro
Maeda, Tetsuo
Takanobu, Morishita
Suzuki, Ritsuro
Fukuda, Takahiro
Ichinohe, Tatsuo
Kurata, Mio
Atsuta, Yoshiko
Kanda, Yoshinobu
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3235
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Once-daily intravenous busulfan versus oral busulfan in children prior to stem cell transplantation: study of pharmacokinetics and clinical outcomes
    Boelens, J. J.
    Bartelink, I.
    Bredius, R.
    Zwaveling, J.
    Bierings, M.
    Rademaker, K.
    Ververs, T.
    van Kesteren, C.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S12 - S12
  • [22] Once-daily intravenous Busulfan versus oral Busulfan in children prior to stem cell transplantation: Study of pharmacokinetics and clinical outcomes
    Boelens, J. J.
    Bartelink, I.
    Bredius, R.
    Zwaveling, J.
    Bierings, M.
    Rademaker, K.
    Ververs, T.
    Kesteren, C. van
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 58 - 59
  • [23] Once-daily vs 4-times daily intravenous busilvex in conditioning regimen before allogeneic stem cell transplantation for patients with myeloid malignancies: Safety and efficacy
    Ben Abdeljelil, Nour
    Hrizi, Ons
    Ben Hmida, Maroua
    Lakhal, Amel
    El Fatmi, Rym
    Torjemane, Lamia
    Belloumi, Dorra
    Ladeb, Saloua
    Ben Othman, Tarek
    BONE MARROW TRANSPLANTATION, 2019, 54 : 220 - 221
  • [24] Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
    Chikako Ohwada
    Shingo Yamazaki
    Katsuhiro Shono
    Kensuke Kayamori
    Yutaro Hino
    Nagisa Oshima-Hasegawa
    Tomoya Muto
    Shokichi Tsukamoto
    Shio Mitsukawa
    Yusuke Takeda
    Naoya Mimura
    Masahiro Takeuchi
    Tohru Iseki
    Masahiro Onoda
    Akira Yokota
    Takaaki Suzuki
    Itsuko Ishii
    Chiaki Nakaseko
    Emiko Sakaida
    International Journal of Hematology, 2021, 114 : 664 - 673
  • [25] Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation (vol 19, pg 1381, 2013)
    不详
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : 290 - 290
  • [26] Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
    Ohwada, Chikako
    Yamazaki, Shingo
    Shono, Katsuhiro
    Kayamori, Kensuke
    Hino, Yutaro
    Oshima-Hasegawa, Nagisa
    Muto, Tomoya
    Tsukamoto, Shokichi
    Mitsukawa, Shio
    Takeda, Yusuke
    Mimura, Naoya
    Takeuchi, Masahiro
    Iseki, Tohru
    Onoda, Masahiro
    Yokota, Akira
    Suzuki, Takaaki
    Ishii, Itsuko
    Nakaseko, Chiaki
    Sakaida, Emiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (06) : 664 - 673
  • [27] Efficacy and safety of once-daily tacrolimus extended-release formulation in allogeneic haematopoietic stem cell transplantation patients
    Katayama, Y.
    Iwato, K.
    Ochi, T.
    Okatani, T.
    Imanaka, R.
    Kyo, K.
    Itagaki, M.
    Asaoku, H.
    Kyo, T.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S445 - S445
  • [28] Randomized comparison of four-times-daily versus once-daily intravenous Busulfan in conditioning therapy for hematopoietic cell transplantation
    Ryu, Seong-Gil
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Jung-Hee
    Lee, Young-Shin
    Seol, Miee
    Hur, Eun-Hye
    Lee, Soo Han
    Bae, Kyun Seop
    Noh, Gyu Jeong
    Lee, Moo-Song
    Yun, Sung-Cheol
    Han, Sang Beom
    Lee, Kyoo-Hyung
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (09) : 1095 - 1105
  • [29] Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomeos
    Zwaveling, Juliette
    den Hartigh, Jan
    Lankester, Arjan C.
    Guchelaar, Henk-Jan
    Egeler, R. Maarten
    Bredius, Robbert G. Maarten
    ANTI-CANCER DRUGS, 2006, 17 (09) : 1099 - 1105
  • [30] Once-daily intravenous busulfan as myeloablative reduced-toxicity conditioning regimen in haematopoietic stem cell transplantation
    Santarone, S.
    Di Bartolomeo, E.
    Bavaro, P.
    Di Carlo, P.
    Olioso, P.
    Papalinetti, G.
    Di Bartolomeo, P.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S374 - S374
12345